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Heme Oxygenase 1 (HMOX1) is an enzyme that catalyzes the reaction that degrades the
heme group contained in several important proteins, such as hemoglobin, myoglobin,
and cytochrome p450. The enzymatic reaction catalyzed by HMOX1 generates Fe2+,
biliverdin and CO. It has been shown that HMOX1 activity and the by-product CO
can downmodulate the damaging immune response in several models of intestinal
inflammation as a result of pharmacological induction of HMOX1 expression and
the administration of non-toxic amounts of CO. Inflammatory Bowel Diseases, which
includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), are one of the most studied
ailments associated to HMOX1 effects. However, microbiota imbalances and infections
are also important factors influencing the occurrence of acute and chronic intestinal
inflammation, where HMOX1 activity may play a major role. As part of this article
we discuss the immune modulatory capacity of HMOX1 during IBD, as well during
the infections and interactions with the microbiota that contribute to this inflammatory
disease.
Keywords: heme oxygenase-1, inflammatory bowel disease, carbon monoxide, infection, inflammation, nuclear
factor erythroid 2-related factor 2, colorectal cancer, microbiota
INTRODUCTION
Heme oxygenase 1 (HMOX1) is an enzyme that catalyzes the first step of the oxidative degradation
of the heme group, which is a rate-limiting reaction that releases the following molecules as
by-products: carbon monoxide (CO), free iron, and biliverdin (which is lately reduced to bilirubin)
(1). HMOX1 is composed of 288 amino acid residues with an active site located between the first
two alpha-helixes (2). The exact reactions leading to the conversion of hemoglobin, hemin, and
myoglobin into bilirubin were identified in 1969, when Tenhunen, Marver, and Schmid described
that this reaction was catalyzed by a heme oxygenase enzyme, based on two observations. First, the
reaction required a metal chelate and the formation of only one isomer of bile pigment, suggesting
the participation of an enzyme in this reaction. Second, the insertion of two hydroxyl groups
that indicated that the cleavage of the porphyrin ring was an oxidative reaction. Based on these
observations, authors described that heme oxygenase stoichiometrically required NADPH and
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molecular oxygen to generate the same amount of carbon
monoxide and bilirubin (3, 4). Few years later, Maines and
Kappas described that, not only heme is a substrate for
heme oxygenase, but also Cobalt protoporphyrin IX (CoPP).
Using microsomal fractions, a NADPH-generating system and
biliverdin reductase, the authors measured CoPP oxidation.
These results suggested that CoPP can be bound to and oxidized
by heme oxygenase, as well as is heme. On the contrary, although
nonreactive metalloporphyrins, such as Ni-heme, bind to the
enzyme these molecules are not oxidized by HMOX1 and inhibit
its enzymatic activity (5). Another important metalloporphyrin
that inhibits HMOX1 activity is tin-protoporphyrin (SnPP), a
molecule that was early evaluated as a potential therapy for
hyperbilirubinemia in newborns, due to its capacity of inhibit the
formation of bile pigments (6). SnPP has the ability to strongly
inhibit heme oxygenase activity by binding to the same site than
does heme and CoPP, competing with these substrate molecules.
At the same time, SnPP treatment increases the amount of heme
oxygenase protein in rat liver cells, probably, as a compensatory
response to the reduced activity of the enzyme (7).
ROLE OF HMOX1 UNDER
PHYSIOLOGICAL CONDITIONS
Although HMOX1 is expressed in all mammalian tissues at
basal levels, expression levels of this enzyme can significantly
increase in cells or tissues where red blood cells or hemoglobin
are degraded by macrophages, such as the spleen, liver, bone
marrow, and kidney. In these tissues HMOX1 expression can
be induced either by substrate (heme) or by other physical
and chemical stimuli, including metalloporphyrins (8), oxidative
stress, pathogen-associated molecular patterns (PAMPs), and
cytokines. The enzyme localization was first described in the
microsomal fraction of spleen and liver cells of Sprague-Dawley
rats (3). The association with the endoplasmic reticulum (ER)
membrane under physiological conditions was later confirmed
for this enzyme (9). However, under stress conditions, HMOX1
is capable of translocating to other cellular membranous
compartments. Under lipopolysaccharide (LPS) and heme
treatments, HMOX1 is found associated with cytochrome
c-containing fractions, suggesting a possible localization in
mitochondria. Stimulation with LPS, heme and hypoxia resulted
in localization in low-density fractions, with high expression
of caveolin-1, the principal structural component of caveolae
or lipid rafts. Furthermore, HMOX1 also colocalized with
NADPH:cytochrome P-450 reductase and biliverdin reductase,
suggesting a functional role of HMOX1 in lipid raft activity (10).
HMOX 1 nuclear localization has also been described in astroglial
cells during differentiation. Confocal microscopy showed that
HMOX1 at day 7 is localized in cytosol and perinuclear region,
moving to the nucleus and nucleolus after 2 and 3 weeks of
differentiation (11). Furthermore, biliverdin reductase has been
localized in nuclear fraction of rat kidney, in response to HMOX1
inducers, LPS and bromobenzene. These data suggest a dynamic
localization for HMOX1 and that this molecule can display
enzymatic activity at the various sites (12).
Because of the wide range of molecules that can trigger
the induction of HMOX1 expression, the complete network of
gene regulation leading to HMOX1 expression is not yet fully
understood. Nevertheless, there are some signaling pathways
and transcription factors that have been well associated with
the HMOX1 response (Figure 1B). The main regulators of
HMOX1 transcription described so far is the transcription factor
Nrf2 [nuclear factor (erythroid-derived 2)-like 2] (13) and the
inducible repressor Bach1 (BTB and CNC homology 1) (14).
Indeed, the effect of CoPP over HMOX1 induction involves the
participation of these two regulators (15). Nrf2 is a basic Leucine
zipper protein that regulates the expression of antioxidant
proteins, as the response to oxidative stress, including HMOX1
(16). Several are the stimuli and signaling pathways leading
Nrf2 to induce HMOX1 expression. For instance, exposure to
the flavonoid Orientin (Ori) can alleviate hydrogen peroxide-
induced oxidative impairment in RAW264.7 cells, by induction
of Nrf2/HMOX1 axis, through c-Jun N-terminal kinases (JNK)
and phosphoinositide-3 kinase (PI3K)/protein kinase B (AKT)
activation (17). Cytokines are another stimuli for HMOX1
expression (18) and it has been demonstrated that in human
macrophages, IL-10 and IL-6-induced expression of HMOX1
required the activation of the signal transducer and activator
of transcription 3 (STAT3) (19). On the contrary, Bach1 is a
repressor of HMOX1 in physiological conditions, when Bach1
is absent, HMOX1 is constitutively expressed (14). Moreover,
a deficiency of Bach1 protects against osteoarthritis and from
oxidative stress-induced injury through the upregulation of
HMOX1 (20, 21).
EVIDENCE SUPPORTING A ROLE FOR
HMOX1 IN INFLAMMATION
The enzymatic activity of HMOX1 was initially associated with
the immune response during inflammatory processes involved
in organs rejection. Early on was observed that the mechanisms
protecting xenografts from being rejected involved a rapid
increase of HMOX1 expression by the endothelial and smooth
muscle cells from mouse cardiac xenografts transplanted into
rats (22). Two years later, experiments performed in a mouse-
to-rat cardiac transplant model showed that the inhibition of
HMOX1 activity by tin-protoporphyrin resulted in an earlier
organ rejection, but when these same rats were additionally
treated with exogenous CO, the long-term graft survival was
restored (23). These studies demonstrated the important role
that HMOX1 can play in the immune modulation involved in
transplants, and that this immunomodulatory effect was driven
by CO (23).
Tardif and collaborators demonstrated that Dendritic Cells
(DCs) treated with lipopolysaccharide (LPS) and CO showed a
diminished capacity to present antigens to T cells and this effect
was due to a reduced fusion of endosomes and lysosomes, that
is required for antigen presentation (24). Such reduced fusion of
endosomes and lysosomes is probably caused by ATP reduction
in the cell, as a result of impaired mitochondrial function
caused by CO (25–27). The activation of adaptive immunity
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FIGURE 1 | Players in the development and progression of IBD and the potential therapeutic effect of Hemoxigenase-1. (A) The pathology of IBD in genetically
susceptible patients is characterized by the recognition of microbiota, pathogens and food antigens developing a pro-inflammatory immune response, with an
augmented production of pro-inflammatory cytokines such as IFN-g, TNF- α, IL-6, and IL-1b. This response triggers tissue damage by the production of reactive
oxygen species (ROS) and Caspase-3, which releases damage-associated molecular patterns (DAMPs) that induces the intestinal inflammation, with high Th17 profile
T cell number, and reduced Treg cells. (B) In some IBD models, treatment with CoPP or CO reduces the pro-inflammatory immune response described above, and
induces the production of anti-inflammatory molecules, such as FoxP3 and IL-10. Consequently, cell death is reduced, diminishing Th17 response. Also, CoPP or CO
increase number of Treg cells. This anti-inflammatory effect result in reduced colitis, suggesting that HMOX1 activity is an important target in the development of new
therapies for IBD.
requires antigen presentation resulting in cytokine secretion,
which finally derives in cell infiltration and inflammation.
Therefore, impaired antigen presentation will result in reduced
inflammation. Another of the HMOX1 effects is the induction of
anti-inflammatory cytokines production, such as IL-10. However,
the interplay between IL-10 and HMOX1 seems to be much
more complex. For instance, in murine macrophages it has been
shown that treatment with recombinant IL-10 induces, in a dose-
dependent manner, HMOX1 production measured by Western
Blot and that such an induction is mediated by the MAPK
p38 activity (28), which is modulated by CO (29). In addition,
HMOX1 induction has been reported to enhance macrophages
polarization into an IL-10-producing anti-inflammatory (M2)
phenotype (30).
The anti-inflammatory properties of HMOX1 have also
conferred it with a protective capacity on different tissues
that have suffered injury. For instance, hypoxia can induce
the secretion of several pro-inflammatory cytokines in lungs,
producing severe inflammation and structural changes of vessels.
Consistently, transgenicmice that constitutively express HMOX1
in the lungs submitted to hypoxia showed that an increased
HMOX1 expression resulted in less inflammation and reduced
vessel hypertrophy, as compared with wild type mice (31).
Furthermore, the pro-inflammatory cytokines and chemokines
expressed in normal conditions were significantly suppressed in
HMOX1 transgenic mice (31). Similarly, the anti-inflammatory
effects of HMOX1 induction were observed in FcγRIIb−/− mice,
which are a model of systemic lupus erythematosus (SLE).
These FcγRIIb−/− mice spontaneously develop proteinuria
and renal inflammation, which are delayed by the induction
of HMOX1 or carbon monoxide treatment. Indeed, carbon
monoxide administration decreased the expansion of CD11b+
cells, prevented the decline of CD4+ FoxP3+ regulatory T
(Treg) cells and reduced the titers of anti-histone antibodies,
as compared to untreated mice (32). It has been also reported
that patients with SLE show reduced expression of HMOX1
in circulating monocytes, suggesting that in myeloid cells,
the expression of HMOX1 could contribute to modulate the
host inflammatory response (33). Moreover, several studies
support the notion that HMOX1 overexpression in the brain
and spinal cord of multiple sclerosis patients could play an
important role in multiple sclerosis patients, which was also
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observed in the experimental autoimmune encephalomyelitis
(EAE) model (34). It has been observed that multiple sclerosis
patients show a decreased expression of HMOX1 inmononuclear
cells from the peripheral blood during disease exacerbation,
similar to SLE patients (33, 35). A recent study has suggested
an association between HMOX1 and HMOX2 polymorphisms
and the risk of developing multiple sclerosis in Spanish
Caucasian men (36). Additionally, possible associations between
variants in HMOX-1 genes and the risk of Parkinson’s disease
have been also reported (37, 38). Furthermore, it has been
also described that HMOX1 is up-regulated during essential
tremor and restless legs syndrome, suggesting a possible
link between these ailments and the activity of HMOX1
(39).
Several studies have also revealed the relationship between
HMOX1 and the pathophysiology of both acute and chronic
intestinal inflammation (40). In the following chapter, we will
discuss the studies performed up to date that support this notion.
FEATURES OF INFLAMMATORY BOWEL
DISEASES
Chronic intestinal inflammation can be triggered by several
conditions, such as infections and autoimmune diseases. It is
characterized by immune cell infiltration, edema and loss of the
epithelium structure (41). The most studied chronic intestinal
inflammations are denominated Inflammatory Bowel Diseases
(IBD). These are chronic inflammatory pathologies of unknown
etiology, which includes Crohn’s Disease (CD) and Ulcerative
Colitis (UC). IBD usually begins in early adulthood, and the
symptoms include recurrent diarrhea, abdominal pain and the
presence of blood in the stool (42). As part of Crohn’s disease,
inflammation can occur in any section of the gastrointestinal
tract, whereas ulcerative colitis is typically confined to the colon
(42). Although in recent years there has been a significant
improvement in understanding the pathophysiology of these
pathologies, their incidence has significantly increased worldwide
and their etiology remains unclear (41). Unfortunately, there is
still no cure for IBD, and the benefits of surgery are usually
only temporary (43). Currently, the treatment of IBD is based
on drugs to reduce symptoms and inflammation, such as 5-
aminosalicylic acid, corticosteroids, immunomodulators, and
biological therapy (44). However, these treatments are only
palliative and most of them can have significant side effects. For
this reason, there is a broad interest to understand in more detail
the pathophysiology of these diseases in order to identify new
therapeutic targets.
Even though the specific cause of IBD is not clear, it is known
that infections, genetic predisposition, and environmental factors
can contribute to disease progression (45–52). Importantly,
several studies on this field suggest that IBD is caused by
an inappropriate immune response to enteric commensal
bacteria in genetically susceptible hosts (53–56). Such an
unbalanced immune response leads to a persistent and relapsing
inflammation of different portions of the gastrointestinal tract
(41). Supporting this hypothesis are genome-wide association
studies that have identified approximately 200 inflammatory
bowel disease-associated loci (57). Most of the genes that have
been linked to IBD are related to host defense against infection,
particularly to the interaction between the host mucosal immune
system and microbes at the epithelial cell surface and inside
the gut lumen (58). The best-known example is the association
of CD with nod2 variants (59). nod2 encodes the primary
receptor for muramyl dipeptide (MDP) and is essential for
bacterial recognition. Defective nod2 prevents the clearance of
intracellular bacteria, due to a deficient antimicrobial response,
which favors the activation of the immune response against the
microbiota (60).
Dysregulation of immune response in the pathogenesis of
IBD is also associated with an imbalance between pro- and anti-
inflammatory molecules involved in both innate and adaptive
immunity, leading to the development of excessive and chronic
inflammation (61). In physiological conditions, the intestinal
mucosa represents a mechanical barrier between immune system
and microorganisms (62) and the abundant immunogenic
stimuli induce infiltration of lymphocytes, monocytes, mast
cells, and eosinophils (63). This physiological response is a
tightly regulated phenomenon, which is important to keep the
integrity of the gastrointestinal barrier (62). However, under
certain pathological conditions this mechanism of control fails,
leading to a persistent detrimental inflammation of the digestive
tract. Along these lines, it has been reported that patients
with IBD display an activated mucosal immune system, with
high infiltration of plasma cells, neutrophils and macrophages,
accompanied by overexpression of pro-inflammatory cytokines
and various chemokines that promote the recruitment of
inflammatory cells (64). Together, cytokines, chemokines,
reactive oxygen species and other mediators result in exacerbated
local inflammation and tissue damage (42) (Figure 1A).
Chronic inflammatory response in CD is characterized by an
abnormal Th1 and Th17 immune responses, which are triggered
by increased mucosal levels of cytokines, including tumor
necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), IL-
12, IL-17, and IL-18 (Figure 1A). In contrast, the production
of IL-4, IL-5, and IL-13 is increased in UC, which leads to a
Th2-polarized immune response. Although in both disorders the
immune response is different, genetically susceptible individuals
have an inappropriate mucosal immune response against their
gut microbiota, mediated by an excessive activation of effector
T cell subsets and/or a deficiency of Treg cells (65) (Figure 1A).
Indeed, Treg cells play a crucial role in the maintenance of
intestinal homeostasis through TGF-β- and IL-10-dependent
mechanisms. For instance, IL-10 is a potent anti-inflammatory
cytokine produced by both Treg and non-Treg cells, capable
of suppressing the production of pro-inflammatory mediators
to limit the inflammatory response. In fact, IL-10-deficient
mice are highly susceptible to colitis, due to aberrant immune
response to commensal bacteria. This abnormal response is more
severe when combined with a deficiency of TGF-β signaling
(66). Previous studies have indicated that IL-10 production
is suppressed in the intestine during IBD. However, the
molecular and cellular mechanisms behind the reduction of
IL-10 secretion observed during IBD have not yet been fully
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understood. In addition, it has been suggested that IL-10 could
induce other molecules with anti-inflammatory activity by a
positive feedback circuit, which leads to the amplification of
this response and the inhibition of intestinal inflammation.
Abnormal low levels of IL-10 during these diseases could
account for the inflammatory imbalance in the intestinal tissue
(67).
As described above, several studies have associated IL-10
production and HMOX1 activity with the development of
IBD (67). Therefore, it has been important to determine the
contribution of the HMOX1 enzyme to the advancement of
intestinal inflammation. Under healthy conditions, HMOX1
expresses in the intestine at low levels, but it is significantly
induced upon triggering of an inflammatory state (68). HMOX1
mRNA expression andHMOX1 protein production are increased
in inflamed colonic mucosa of UC patients. In addition, HMOX1
expression is also decreased in mononuclear cells from colonic
submucosa from UC patients, as compared to normal mucosa
from healthy subjects (69). Similar data were obtained during
the occurrence of three different inflammatory conditions:
Helicobacter pylori-positive gastritis patients, active UC and
active CD. Immunohistochemical staining showed a higher
expression of HMOX1 in gastric mucosa of Helicobacter pylori-
positive gastritis patients and in colonic mucosa of active UC and
active CD patients, as compared to healthy controls (70). In the
next section, studies performed to evaluate the effect of HMOX1
modulation in IBD will be discussed.
POTENTIAL THERAPEUTIC USE OF
HMOX1 MODULATION AND CO
PRODUCTION FOR IBD
The contribution of HMOX1 to the prevention or reduction of
intestinal inflammation has been shown in different models of
IBD, which are summarized in Table 1. It has been reported
that in the model of colitis induction by the administration of
Dextran Sulfate Sodium (DSS) an increase in the expression of
HMOX1 led to an amelioration of the intestinal inflammation.
Induction of HMOX1 by intraperitoneal injection of CoPP
at day 1 and 3 after DSS treatment significantly reduced the
intestinal histological damage as compared to control animals
(72). Another study also described the cytoprotective role of
HMOX1 in the model of colitis induced by DSS in mice.
In this study, a treatment with hydrogen-rich water was
performed in mice treated with DSS, resulting in decreased
inflammation and disease score, increased level of anti-oxidative
markers and reduced production of inflammatory molecules.
Importantly, it was shown that this treatment up-regulated
HMOX1 expression (78). In support of this observation, another
study showed that mice treated with the HMOX1 inducer
hemin previous to the induction of DSS colitis displayed
reduced histological damage, which was associated to an
increased expression of HMOX1. Furthermore, a decreased
proportion of Th17 cells and increased number of Treg
cells were found in mesenteric lymph nodes (MLN) and
spleen of hemin-pretreated mice that were exposed to DSS
(77).
Another mouse model of colitis induction, in which the
effect of HMOX-1 was evaluated, is the treatment with
2,4,6-trinitrobenzene sulfonic acid (TNBS). Both HMOX1
mRNA expression and enzymatic activity were induced after
TNBS treatment. Further, when the HMOX1 inhibitor tin
mesoporphyrin (SnMP) was used in these assays, HMOX1
activity was reduced and colonic damage increased (71).
An analysis of the role of HMOX1 and IBD has been also
performed using patient samples, including both in vitro and
in vivo experiments. In these studies, IBD patients showed
a heterogeneous distribution of HMOX1 expression in the
colonic mucosa, as compared to patients with intestinal damage
produced by conditions different from IBD, such as diverticulitis.
During these ailments the expression of HMOX1 was shown
to be highly increased in epithelial cells of colonic crypts
and in macrophages (72). Consistently, some drugs used in
patients with IBD have shown to have a beneficial effect through
the induction of HMOX1. For example, it was demonstrated
that 5-aminosalicylic acid (5-ASA), an anti-inflammatory drug
often used to treat IBD, reduces the TNBS-provoked colonic
inflammatory injury in rats, by increasing colonic HMOX1
activity (79). Another example is Tranilast, a mastocyte stabilizer
used in some countries as IBD treatment. The simultaneous
intrarectal administration of DSS and Tranilast to C57BL/6
mice resulted in an attenuated colitis, produced by low pro-
inflammatory cytokines, increased anti-inflammatory cytokines
and promoted HMOX1 expression (80). In another field,
in vitro studies have demonstrated that treatment with plant
extracts of Atractylodes macrocephala (AM) or Taraxacum herba
(TH) increased HMOX1 production. Oral pre-administration
of AM and TH can rescue mice from DSS-induced colitis by
inhibiting inflammatory mediators via inactivated extracellular
signal regulated kinase (ERKs) and repressed NFκB and signal
transducer and activator of transcription 3 (81).
Given that HMOX1 might be involved in the immune
processes leading to intestinal inflammation, CO has been
considered as a therapeutic tool to reduce the symptoms of
this disease (82). The first evidence supporting that CO could
work as a therapy for IBD is the observation that smoking
can work as a protective factor in UC patients (83, 84). It
was shown that exposure to CO ameliorates chronic intestinal
inflammation in IL-10−/− mice by interfering with the IFN-γ
signaling that mediates inflammation in this model (73). Similar
results were found in another murine model of IBD. In this case,
mice were treated with TNBS to induce intestinal inflammation,
and CO gas was administrated intrarectally at 200 ppm per
day. TNBS- and CO-treated mice showed significantly smaller
ulcers in colon, less colon weight and reduced myeloperoxidase
(MPO) activity. Further, CO-treated mice showed reduced
thiobarbituric acid (TBA)-reactive substances and cytokine-
induced neutrophil chemoattractant 1 (CINC-1) expression in
colonic mucosa, as compared with TNBS-air treated mice (75).
In a necrotizing enterocolitis rat model, inhaled CO gas also
protected against intestinal inflammation and decreased levels
of TNF-α (74). However, exposition to CO is not the only way
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TABLE 1 | Protective effect of HMOX1/CO in inflammatory intestinal models.
Model/disease Treatment Route of
administration
Effect Animal
model
Reference
TNBS-induced colitis SnMP (inhibitor of
HMOX1 activity)
Subcutaneous Increase of colonic damage
Enhance ROS and iNOS
Rat (71)
DSS-induced colitis CoPP (inductor of
HMOX1 expression
Intraperitoneal Reduction of IFNγ in mLN
Reduction of apoptotic epithelial cells in colon
Mouse (72)
IL-10−/− mice CO gas Air exposure Reduction of IL-12 p40 and TNF intestinal
secretion
Mouse (73)
Necrotizing
enterocolitis
CO gas Air exposure Reduction of serum IL-1β, TNFα, and nitrites Rat (74)
TNBS-induced colitis CO gas Intrarectal Reduction of ulcer area and wet colon weight
Inhibition of MPO activity, TBA-reactive
substances, and CINC-1 expression
Rat (75)
TNBS-induced colitis CORM-3 (CO releasing
molecule 3)
Intraperitoneal Reduction of MPO activity, TNFα, IFNγ, and
IL-17A expression
Mouse (76)
DSS-induced colitis Hemin (inductor of
HMOX1 expression
Intraperitoneal Decrease of colitis symptoms and histological
damage
Decrease in proportion of Th17 cells and
increased number of Treg in spleen and mLN
Mouse (77)
ROS, reactive oxygen species; mLN, mesenteric lymph nodes; MPO, myeloperoxidase; TBA, thiobarbituric acid; CINC-1, cytokine-induced neutrophil chemoattractant 1.
to administrate low doses of CO. Carbon monoxide-releasing
molecules (CORM) have been widely used to corroborate the
effectiveness of CO. A study showed that intraperitoneal CORM-
3 injection in mice for 3 days prior to TNBS treatment attenuated
distal colon damage and histological score. In an in vitro
approximation, CORM-3 treatment reduced IFN-γ and TNF-α
in CD4+ T cells stimulated with anti-CD3/CD28 antibodies (76).
The evidences listed in Tables 1, 2 support the important role
of HMOX1 during the pathology of IBD in animal models and
in humans. However, to elucidate the molecular mechanism of
HMOX1 activity would help to understand those effects and to
the development of new potential therapies for IBD (Figure 1B).
INTERPLAY BETWEEN HMOX1 AND
MICROORGANISMS IN THE
GASTROINTESTINAL TRACT
An important cause of intestinal inflammation is the infection
by pathogenic bacteria, such as Salmonella enterica. Although
little is known about the exact effect of HMOX1 on bacterial
infections, it has been described that HMOX1 plays a role in
the clearance of Salmonella by the immune system. For instance,
in an acute inflammation model, where C57BL/6 mice were
treated with streptomycin to eliminate the microbiota, prior
to Salmonella enterica serovar Typhimurium (S. Typhimurium)
oral infection, treatment with CoPP reduced the presence of
SalmonellaDNA in the mesenteric lymph nodes, lamina propria,
liver and spleen (90). Furthermore, in vitro depletion of HMOX1
in murine macrophages reduced these cells bactericidal activity
against E. coli, Enterococcus faecalis and S. Typhimurium. These
data suggest that the observed CO effect is due to the capacity
to promote bacterial clearance in phagocytic cells associated
to the intestine (90). A recent in vitro study supports these
findings, in which the bacterial clearance capacity of murine
and human macrophages was tested. Specifically, it was observed
that in HMOX1-deficient mice, macrophages have bacterial
killing defects that were restored with the administration of
CO. Further, CO treatment results in an enhanced bacterial
clearance capacity in mouse and human macrophages (91).
In contrast, CO has no effect on bactericidal activity of
macrophages isolated from NALP3-deficient and caspase3-
deficient mice. Consequently, the capacity of macrophages
of killing bacteria depends on CO-mediated inflammasome
activation (91). However, apparently contradictory results were
observed in murine macrophages transfected with hmox1
shRNA. In these macrophages, intracellular S. Typhimurium
survival was reduced upon hmox1 knockdown, an effect
attributed to iron availability inside the cell (92).
Other bacteria that can be affected by the action of HMOX1
in the intestine are members of the intestinal microbiota.
Recent research has revealed that alterations in the intestinal
microbiota play a key role in the development of colitis and
other inflammatory conditions of the gut (55). For example, there
are studies that support an interaction between the host and
molecules produced by commensal bacteria. Some of these are
Short Chain Fatty Acid (SCFA), such as acetate, butyrate and
propionate, which can promote an anti-inflammatory response
in the intestine (93).
In addition, when C57BL/6 mice are exposed to specific
pathogen free (SPF) enteric microbiota after been raised under
germ free conditions, colonic HMOX1 expression is increased
almost 6 times, and this induction depends on IL-10 and Nrf2
(90). These data support the notion that HMOX1 not only works
by inducing an anti-inflammatory cytokine profile, but also by
interacting with intestinal microbiota.
As well as mammals, other organisms have enzymes with
functions equivalent to HMOX1. It has been described that
Frontiers in Immunology | www.frontiersin.org 6 September 2018 | Volume 9 | Article 1956
Sebastián et al. HMOX1 as a Modulator of Intestinal Inflammation
TABLE 2 | Protective effect of different compounds in inflammatory intestinal models that involves HMOX1 pathways.
Model/disease Treatment Route of
administration
Effect Animal
model
Reference
TNBS-induced colitis 5-ASA (5-aminosalicylate) Intracolonic Reduction of macroscopic colonic inflammation, MPO
activity, and TNFα levels
Rat (79)
DSS-induced colitis Tranilast Intrarectal Amelioration of clinical symptoms of colitis
Decrease in number and degranulation of mast cells in
colon
Decrease of TNFα, IFNγ, and IL-6 expression in colon
Increase of IL-10 expression in colon
Mouse (80)
DSS-induced colitis HRW (Hydrogen-rich water) Intraperitoneal Attenuation of macroscopic and microscopic colonic
damage scores
Reduction of MDA and MPO, expression in colon.
Reduction of TNFα, IL-6, and IL-1β in blood
Mouse (78)
DSS-induced colitis Atractylodes macrocephala
and Taraxacum herba plant
extracts
Gavage Inhibition of iNOS, IL-1β, and TNFα expression in colon Mouse (81)
DSS-induced colitis Hyperoside (flavonoid) Gavage Reduction in TNFα, IL-6, COX-2 and NF-κB p65
expression in colon
Mouse (85)
DSS-induced colitis Ginger active compound
(6-shogaol)
Oral Reduction of TNFα, IL-6, IL-1β, and iNOS expression in
colon
Mouse (86)
Adoptive T-cell transfer
model of chronic colitis
Quercetin (flavonoid) Oral Reduction of TNFα, IL-23, IL-12p40 expression in lamina
propria lymphocytes
Mouse (87)
Acetic acid-induced
colitis
Ziziphus spina-christi fruit
extract
Gavage Reduction of LPO, NO and MPO activity
Induction of antioxidant activity (SOD, CAT, GPx, GRd)
Rat (88)
DSS-induced colitis Alpinetin (flavonoid) Oral Reduction of macroscopic damage scores
Upregulation of occludin, zonula occludens-1 and SOD
expression
Downregulation of claudin-2
Mouse (89)
MDA, Malonaldehyde; COX-2, cyclooxygenase-2; LPO, lipid peroxidation; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; GRd, glutathione reductase.
some bacteria express heme-degrading proteins that act as a
complex group of molecules that work together to catalyze heme
degradation (94, 95). Some enteric pathogens and commensal
bacteria express this HMOX1 homolog, which may affect
intestinal immune response. Corynebacterium diphteriae has a
heme-oxygenase (HmuO) that has 33% sequence identity and
70% of homology with human HMOX1 (96). Most of the known
bacterial HO are described for pathogens, such as Yersinia pestis
(Hmu),Neisseriae spp. (HemO), Pseudomonas aeruginosa (PigA),
Mycobacterium tuberculosis (MhuD), and Staphylococcus aureus
(IsdG, IsdI). All of these bacteria harbor genes forHO that encode
functional proteins (94, 97–101).
Some strains of E. coli have a heme uptake gene cluster that
is required for harnessing available iron in the environment,
presented as heme group. Bacterial analog of HMOX1 called
ChuS is encoded by chuS. Metabolic products are the same as
human HMOX1. For instance, HO enzyme of E. coli O157:H7
produces CO efficiently, despite having a different structure
from HMOX1. Additionally, enteric bacteria as Enterobacter and
Shigella may have similar proteins (95, 102). Other proteins that
are involved in heme uptake machinery are heme receptor called
ChuA (103) present in the outer membrane, periplasmic protein
ChuT which binds to heme, inner membrane protein ChuU and
the ATPase ChuV (104) (Figure 2B).
A recent study described the anti-inflammatory action of an
E. coli strain isolated from mice gut, named NC101, which has
chuS gene. In mono-association studies, germ-free SvEV/129
IL-10 deficient mice were treated with this bacterial strain.
A correlation was found between chuS expression on feces
and the progression of inflammation. In addition, composition
of intestinal bacteria was altered when C57BL/6 wild type
mice were exposed to carbon monoxide for 14 days. Also,
chuS expression was increased in that point. Interestingly these
changes returned to baseline after 14 days without CO exposure.
Additionally, when BMDMs were cultured with an E. coliNC101
strain that overexpresses chuS pro-inflammatory cytokine IL-
12p40 production was decreased. On the other hand, IL-10
production increased, promoting an anti-inflammatory scenario.
These changes in cytokines expression were promoted by a
soluble factor released by bacteria. Finally, CO abundance found
in liver of mice infected with the strain that overexpresses chuS
was higher than in those infected with a strain that lacks chuS.
Moreover, in the first group of mice mentioned before expression
of HMOX1 and Nqo1 were significantly increased same as IL-10
production (105).
These in vitro and in vivo findings contribute to the hypothesis
that ChuS may be used to modulate immune response in an
inflammation context (Figure 2A). A probiotic strain with ChuS
enzyme may be able to decrease inflammation in the gut by
secreting CO as a product of heme uptake process. CO would
act in host cells (gut epithelium) modulating IL-12p40 and
IL-10 expression and production. Consequently, inflammation
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FIGURE 2 | Heme uptake and degradation by gram negative bacteria. Microbiota is in constant interaction with the epithelial cells. (A) In an inflammation context in
the intestine some bacteria may modulate immune response. (B) That is the case of a probiotic strain with ChuS. These bacteria have an outer membrane receptor
(ChuA) catches specifically heme group. Periplasmic protein (ChuT) binds substrate and carry it to inner membrane protein (ChuU), where ATPase direct the transport
of the substrate to the cytoplasm. There, HMOX1 analog (ChuS) binds heme group and catalyzes its degradation. CO is a product of this reaction and may be
released to the environment where it exerts its anti-inflammatory effect on host cells.
will be ameliorated, leading to an anti-inflammatory scenario
(Figure 2B).
HMOX1 AS A CANCER TARGET
Another aspect of intestinal inflammation where HMOX1 is
involved is cancer. HMOX1 has been associated with different
types of cancer (106), including prostate cancer (107), bladder
cancer (108), skin cancer (109), and colorectal cancer (CRC).
The latter is an important issue due to all the evidences
that support the hypothesis that HMOX1 is a key immune
modulator in intestine. It has been demonstrated that HMOX1
is highly expressed in CRC (110) and high expression of
HMOX1 in small-intestine adenocarcinomas is associated with
lower pT (primary tumor) category, less pancreatic invasion
and longer overall survival than those with low HMOX1
expression (111). Another study also showed that HMOX1 was
over-expressed in human invasive CRC, associated with longer
overall survival time. Using 1,2-dimethylhydrazine (DMH)-
induced CRC animal model, the authors showed that HMOX1
expression is enhanced as tumor progress, and that this effect
is due to the induction of cell cycle arrest and apoptosis
(112). In vitro studies also showed augmented expression of
HMOX1 in primary colon cancer tissues and HCT116 colon
cancer cells compared with normal surrounding tissue and with
normal epithelial cell line, respectively. Moreover, treatment
with CORM-3 inhibited cell proliferation of HCT116 cells
(113). An important feature of intestinal immune response are
macrophages. Particularly, CX3CR1+ macrophages contribute to
intestinal homeostasis, controlling T cell response to commensal
bacteria (114, 115). CX3CR1 deficient mice could not resolve
intestinal inflammation in azoxymethane (AOM)/DSS-induced
colitis-associated cancer and have higher colitis score and
polyps, compared with wildtype mice. These authors showed
that CX3CR1 deficient mice has lower HMOX1 expression in
adenomatous colon tissues, and treatment with CoPP restored
the recovery reducing intestinal inflammation and preventing
carcinogenesis (116).
Based on all these evidence, HMOX1 has been proposed
as a target for cancer treatment (106), including its inducible
repressor BACH1 (117), or its positive regulator Nrf2 (118).
CONCLUDING REMARKS
Since HMOX1 was originally described, strong evidence has
supported the notion that this enzyme is a major modulator
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of immune response in several pathologies. Given that the
number of IBD cases is increasing worldwide, it is very
important to bring to light the etiology of these chronic diseases
and new therapeutic alternatives. The evidences discussed
in this review support the notion that HMOX1 activation
reduces inflammation in the gut in several animal models
of IBD, through the induction of anti-inflammatory cytokines
pathways. Importantly, it has been demonstrated an association
between IBD development and genes involved in the proper
immune response to infecting microbes. Although the exact
relation between HMOX1 and microorganisms colonizing—or
infecting—the gastrointestinal tract is not totally elucidated yet, it
is interesting that enzymes with similar functions than HMOX1
have been described in bacteria, particularly ChuS. Importantly,
this bacterial enzyme has been associated with the induction
of an anti-inflammatory environment in a mouse colitis model
(105). Therefore, intestinal bacterial might be contributing to
prevent intestinal inflammation through the byproducts of
HMOX1 enzymatic activity. Furthermore, intestinal infections
are an important factor in the development of IBD (51) and
most of the evidence available to date supports the notion that
HMOX1 promotes bacterial clearance, diminishing intestinal
inflammation (90). Moreover, it has been demonstrated that CO
can interact directly with heme groups of the bacterial electron
transport chain, suggesting that HMOX1 has an effect in bacterial
infections not only through the modulation of the immune
response, but by the direct interaction with the pathogen (119).
In another field, HMOX1 has also been associated with colorectal
cancer, being suggested as a novel target for cancer therapy
(106).
Because of the existing evidence of HMOX1 role in intestinal
inflammation, many therapy targets can be proposed. Given
that most of the anti-inflammatory and cytoprotective effects of
HMOX1 have been attributed to CO, this could be an effective
treatment. However, it is well known that CO in mammals is
toxic from determined concentrations. For these reasons, it is
very important to elucidate the exact mechanisms by which
HMOX1 and CO are exerting all the effects described here, in
order to design novel therapeutic strategies to deliver CO in a
safe manner.
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